Navigation Links
Cystic Fibrosis Trial In Children Returns Positive Data
Date:4/3/2008

ria Subjects with a known diagnosis of cystic

fibrosis, FEV1 < 70% of predicted, of either

gender, aged between 8 and 19 years of age and

currently receiving rhDNase or eligible to

receive rhDNase.

Primary End Points To compare and contrast the effect on FEV1 of:

1: Bronchitol to rhDNase

2: Bronchitol + rhDNase to rhDNase

Secondary End Points To assess whether:

1: the effects of Bronchitol are additive to

rhDNase

2: Bronchitol reduces the bacterial load in

the lung

3: the effects of Bronchitol are beneficial

to quality of life

Trial Location United Kingdom

Commercial partners Pharmaxis Ltd

Sponsor Investigator initiated, Pharmaxis supported

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that w
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients
2. Genetic manipulation might model cystic fibrosis
3. Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis
4. Data show a decline in cystic fibrosis since introduction of prenatal carrier screening
5. Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections
6. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
7. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
8. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
9. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
10. Synosia Starts Phase II Efficacy Trial For Rufinamide
11. IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Cynvenio, a cancer ... through the genomic analysis of tumor cells in the ... a web-based cancer decision support application powered by CollabRx, ... Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast ...
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health ... behavior change technology, today announces that EmblemHealth , ... and wellness company, is now providing the RedBrick Compass ... coaching program, to all of its members. EmblemHealth is ...
(Date:1/15/2014)... A study has been launched to test whether technology ... help to tackle the problem of obesity.  This unique healthcare ... based in Stowmarket) and academics at University Campus Suffolk is ... which is inspired by equipment used to collect data about ...
(Date:1/15/2014)... Two champions of science, technology, engineering, and ... annual competition for middle and high school students designed ... study. The competition presents students with real-world problems experienced ... Mathematics, and Sciences is a program administered by ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: ... been named the 2009 Life Sciences Company of the ... presented by LifeSciences British Columbia to recognize a local ... of British Columbia,s life sciences industry. This award recognizes ...
... Calif., April 9 Cell Biosciences, a provider of ... the closing of a $10 million Series C financing ... Existing investors Domain Associates, Latterell Venture Partners, Novo A/S, ... Group also participated in the financing."We are very happy ...
... April 9 Cepheid (Nasdaq: CPHD ) today ... first quarter ended March 31, 2009, on Thursday, April 23, ... a management presentation at 2 p.m. Pacific Time on Thursday, ... the live webcast, please visit Cepheid,s website at ...
Cached Biology Technology:OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia 2OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia 3Cell Biosciences Closes $10 Million Series C Financing 2Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast 2
(Date:4/17/2014)... IPCC meeting painted a stark warning on the possible ... a greenhouse effect 32 times that of carbon dioxide. ... humic substances act as fully regenerable electron acceptors which ... in wetlands instead of being released to the atmosphere. ... disrupted it may enter into a vicious cycle to ...
(Date:4/17/2014)... process whereby the genetic information of DNA is ... which have numerous different functions in living organisms. ... during gene expression, by relating the genetic information ... manufacturing proteins. , By examining the different ... an organism at a given time, researchers can ...
(Date:4/17/2014)... have uncovered a new way the immune system may ... efforts to use immune cells to treat illness. , ... the immunological equivalent of "neighborhood police" specialized squads ... organ, instead of an entire city, the body. , ... Louis have shown that the liver, skin and uterus ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Rapid and accurate mRNA detection in plant tissues 2Some immune cells defend only 1 organ 2
... dominant male and female to reduce their personal contribution to ... in Functional Ecology . , By removing the large ... cycle in this species a team from the University ... investment strategies of the dominant pair and the survival of ...
... Albert Einstein College of Medicine of Yeshiva ... as its twelfth Institutional Founding Member (IFM). A collaboration ... organizations, NYGC aims to transform medical research and clinical ... facilities in North America. "Einstein is pleased to ...
... directly lead to new ways of designing trials that would ... next few years and could change outcome for patients." ... 2013 will build on topics discussed in previous years and ... video here[ http://www.youtube.com/watch?v=X_anpC5WZPg ]: Breast cancer heterogeneity ...
Cached Biology News:Einstein joins the New York Genome Center as 12th institutional founding member 2IMPAKT -- Translational research breast cancer conference 2IMPAKT -- Translational research breast cancer conference 3
...
... the Adept CE 4100 high pressure dual piston ... wavelength detector for added flexibility. The ... and interface unit, CE 4901., The CE 4901 ... be used with Windows 98 and 2000, offers ...
Bis-Acrylamide (bis) is a monomer used as a crosslinker with acrylamide to form polyacrylamide electrophoretic gels. This 2% bis solution is supplied as 500 ml....
... G|2 Doublestain System is a high-sensitivity ... kit. The kit is intended for ... detection of two different antigens within ... with suitably diluted rabbit and mouse ...
Biology Products: